• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes

byKassandra McFarlaneandSze Wah Samuel Chan
July 4, 2022
in Chronic Disease, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The pathologic response rate was similar in the atezolizumab treatment group as compared to placebo.

2. There were more frequent serious adverse events in the atezolizumab group compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: In roughly 15-20% of breast carcinomas, human epidermal growth factor receptor 2 (HER2) is overexpressed and results in an aggressive cancer with poor outcomes. Because of their targeted effects on HER2, pertuzumab and trastuzumab (PH) therapy in combination with chemotherapy is the standard of care for HER2-positive early breast cancer (EBC). This study aimed to determine the effect of combining atezolizumab, a programmed cell death-ligand 1 (PD-L1) inhibitor, with the standard of care treatment for HER2-positive EBC on outcomes of pathologic complete response (pCR) rate, event-free survival (EFS), and safety. The pCR rates for the azetolizumab group was 62.4% and for the placebo group it was 62.7%. In the PD-L1-positive subgroup, pCR rates were 72.5% for placebo and 64.2% with atezolizumab. In the PD-L1-negative subgroup, pCR rates were 53.8% for placebo and 60.7% for atezolizumab. There were more patients in the azetolizumab group that had an EFS event than in the placebo group (5.3% compared to 3.1%, respectively). Neither group had an estimable median EFS. There were a greater frequency of serious adverse events (AEs) in the azetolizumab group compared to placebo. There were 2 fatal AEs that were attributable to azetolizumab treatment (alveolitis and septic shock). Limitations to this study include small sample size in some of the subgroups as well as limited power of the study to determine long-term outcomes. Overall, the standard of care treatment for HER2-positive EBC is not improved by the addition of azetolizumab.

Click to read the study in The Journal of Clinical Oncology

Relevant Reading: A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study.

In-Depth [randomized controlled trial]: This international, multi-centre, randomized, controlled trial included 454 adult patients assigned in a 1:1 fashion to receive neoadjuvant dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and PH (ddAC-PacPH) with either atezolizumab (n = 226) or placebo (n = 228). There were 109 patients in each of the placebo and treatment group with PD-L1-positive tumours There were 119 and 117 patients in the placebo and treatment group, respectively, with PD-L1-negative tumours. The pCR rates for the azetolizumab group was 62.4% and for the placebo group it was 62.7% (a difference of -0.33%; 95% confidence interval (CI), -9.23 to 8.57%). The pCR rates were 72.5% for placebo and 64.2% with atezolizumab in the PD-L1-positive subgroup (a difference of -8.26%; 95% confidence interval (CI), -20.56 to 4.04%). pCR rates were 53.8% for placebo and 60.7% for atezolizumab in the PD-L1-negative subgroup (a difference of 6.90%; 95% CI, -5.29 to 19.49%). For EFS, 3.1% in the placebo group and 5.3% of the azetolizumab group experienced an event, with neither group having an estimable median EFS. AEs of grade 3 or 4 were more common in the treatment group. All five of the grade 5 AEs that occurred during the trial were in the azetolizumab group. Two fatal AEs were found to be attributable to treatment with azetolizumab.

RELATED REPORTS

Addition of atezolizumab to FOLFOXIRI and bevacizumab led to limited increase in survival in metastatic colorectal cancer

Neoadjuvant nivolumab with chemotherapy increases survival in resectable non-small-cell lung cancer

Tiragolumab with atezolizumab is a promising treatment option for PD-L1 positive advanced non-small-cell-lung cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: AtezolizumabHER2-positive breast cancerneoadjuvant immunotherapy
Previous Post

FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option

Next Post

Sickle cell trait associated with preexisting kidney comorbidities and increased COVID-19 mortality

RelatedReports

Patient Basics: Colonoscopy
Oncology

Addition of atezolizumab to FOLFOXIRI and bevacizumab led to limited increase in survival in metastatic colorectal cancer

June 6, 2022
Surgical site anesthetic infusion may enhance analgesia after mastectomy
Oncology

Neoadjuvant nivolumab with chemotherapy increases survival in resectable non-small-cell lung cancer

May 30, 2022
Complement mutation linked to poor response to eculizumab
Oncology

Tiragolumab with atezolizumab is a promising treatment option for PD-L1 positive advanced non-small-cell-lung cancer

May 23, 2022
Oncology

Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer

April 18, 2022
Next Post
Stem cell transplant may be effective in sickle cell disease

Sickle cell trait associated with preexisting kidney comorbidities and increased COVID-19 mortality

Galcanezumab reduces the frequency of episodic cluster headaches

Cognitive behavioral therapy efficacious for treatment of comorbid posttraumatic headache and posttraumatic stress disorder symptoms among US veterans

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Newborn screening for cystic fibrosis improves nutritional outcomes
  • BNT162b2 vaccine reduces rates of COVID-19 omicron variant infection in children
  • Non-contrast CT sensitive and specific for kidney stones [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.